On August 9 2023, DECIPHERA PHARMACEUTICALS ($NASDAQ:DCPH) announced their Q2 FY2023 earnings results, showing a total revenue of USD 38.3 million – a 17.9% rise from the previous year. Net income, however, declined to USD -48.6 million, compared to the prior year’s -43.1 million.
GoodWhale’s analysis of DECIPHERA PHARMACEUTICALS‘ financials has revealed that the company is classified as a ‘cheetah’ according to the Star Chart. This type of company typically has achieved high revenue or earnings growth, but is considered less stable due to lower profitability. Investors interested in this type of company may be those looking to take advantage of potential growth, but also those who are comfortable with a higher level of risk. DECIPHERA PHARMACEUTICALS has an intermediate health score of 5/10 when it comes to cashflows and debt, which suggests it has the capacity to sustain future operations in times of crisis. Further analysis shows that DECIPHERA PHARMACEUTICALS is strong in asset and growth, but weaker in terms of dividend and profitability. It is therefore important for investors to consider all these factors before investing in the company. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Deciphera Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Deciphera Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Deciphera Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Deciphera Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The pharmaceutical industry is a highly competitive marketplace.
However, the company faces stiff competition from a number of other companies, including Cardiol Therapeutics Inc, Redhill Biopharma Ltd, and SCYNEXIS Inc. Each of these companies has a strong presence in the industry and is well-positioned to compete for market share.
– Cardiol Therapeutics Inc ($TSX:CRDL)
Cardiol Therapeutics Inc is a Canadian biopharmaceutical company focused on the research and development of therapies for heart failure. The company has a market cap of 43.98M as of 2022 and a Return on Equity of -40.02%. Cardiol’s lead product candidate is CD101, an investigational therapy for the treatment of heart failure. CD101 is currently in a Phase II clinical trial.
– Redhill Biopharma Ltd ($NASDAQ:RDHL)
Redhill Biopharma Ltd is a publicly traded biopharmaceutical company. The company’s focus is on the development and commercialization of therapies for gastrointestinal diseases and cancer. The company’s lead product, TALICIA, is approved in the United States for the treatment of Helicobacter pylori infection. The company’s second product, RHB-105, is being developed for the treatment of H. pylori infection and gastric cancer. The company has a market cap of $39.57M and a ROE of -2625.79%.
SCYNEXIS Inc is a biopharmaceutical company that focuses on the development and commercialization of anti-infective therapies. The company’s market cap is $73.14 million and its ROE is -72.72%. SCYNEXIS Inc’s main product is its lead drug, ibrexafungerp, which is in clinical development for the treatment of fungal infections.
Deciphera Pharmaceuticals reported its FY2023 Q2 earnings results on August 9, 2023, with total revenue of USD 38.3 million, a 17.9% year-on-year increase. Net income was reported at USD -48.6 million, a decrease from the previous year’s figure of -43.1 million. Despite the decrease in net income, the stock price increased on the same day.
In light of this news, investors can view this as an opportunity for a long-term investment in Deciphera Pharmaceuticals, based on the company’s potential for future growth and profitability. The 17.9% year-on-year revenue increase is indicative of strong performance despite the decrease in net income, and highlights the company’s potential for future financial success.